Skip to content

Comparing pain relieving effect of a drug named ketorolac with local anaesthetic in upper limb nerve block for surgeries of upper limb fractures.

A comparitive evaluation of analgesic efficacy of ketorolac as adjuvant with ropivacaine in ultrasound-guided supraclavicular nerve block in patients undergoing upper limb surgeries: A prospective randomised controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080450
Enrollment
120
Registered
2025-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group KB - Ketorolac given perineurally through supraclavicular block: Group KB will receive supraclavicular block with injection ropivacaine 0.5% 20 ml with ketorolac 1 ml (30 mg) and
and 30 mg ketorolac will be administered i.v. in 100 ml of normal saline over 15 minutes. Control Intervention1: Group C - Ketorolac will not be given through any route in this group: Group C will rec

Sponsors

AIIMS Rajkot
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA physical status 1 and 2 2. BMI 20-30 kg/m-2 3. Patients scheduled for upper limb surgeries below the level of shoulder.

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. Coagulopathy 3. Patients with known allergy to local anaesthetics or NSAIDS 4. Patients with known neurological deficit involving brachial plexus 5. Patients with hepatic or renal or gastrointestinal dysfunction 6. Pregnant or lactating patient 7. Infection at local site

Design outcomes

Primary

MeasureTime frame
1.Primary: Time to first rescue analgesic requestTimepoint: At any poit of time between 0-24 HOURS

Secondary

MeasureTime frame
a) Onset and duration of sensory and motor anaesthesia b) VAS scores at rest and movement during 24 hours period c) Haemodynamics and adverse effects (if any) Timepoint: At 0min, 5min, 10min, 15min, 20min, 30min, 60min, 2hr, 4hr, 6hr, 12hr and 24hrs

Countries

India

Contacts

Public ContactDr Anita Saran

AIIMS Rajkot

khushboo0411@gmail.com9888530182

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026